The use of recombinant human growth hormone in patients with Mucopolysaccharidoses and growth hormone deficiency: a case series.

Alessandro CattoniS MottaN MaseraS GasperiniA RovelliR Parini

Published in: Italian journal of pediatrics (2019)

Recombinant human growth hormone appears to have effectively reverted the growth deceleration experienced by MPS patients diagnosed with growth hormone deficiency, at least during the first 12-24 months of treatment.

Keyphrases

growth hormone
recombinant human
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
replacement therapy
peritoneal dialysis
smoking cessation
patient reported